PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33851691-3	2021	Ibrutinib, a first-in-class BTK inhibitor, has been approved for the treatment of several types of B-cell malignancies worldwide.	ibrutinib	0-9	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	28-31	
33851691-4	2021	However, ibrutinib has off-target activities on non-BTK kinase that are related to adverse effects or might translate into clinical limitations.	ibrutinib	9-18	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	52-55